Paper41555342
ESM1 and protein lysine L-lactylation modification (Pan-kla) in ovarian cancer: coexpression, clinical significance, and prognostic value.
Zhou W and 6 others. Diagn Pathol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. ESM1 and protein lysine L-lactylation modification (Pan-kla) in ovarian cancer: coexpression, clinical significance, and prognostic value. Papers, record 41555342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41555342
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- ESM1 and protein lysine L-lactylation modification (Pan-kla) in ovarian cancer: coexpression, clinical significance, and prognostic value.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ovarian Neoplasms | Major topic |
| Biomarkers, Tumor | Major topic |
| Neoplasm Proteins | Major topic |
| Humans | |
| Female | |
| Prognosis | |
| Middle Aged | |
| Aged | |
| Adult | |
| Tumor Microenvironment | |
| Immunohistochemistry | |
| Lysine | |
| Proteoglycans |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82303246 | the Natural Science Foundation of China | PubMed | ||
| 2025JJ50493 | the Natural Science Foundation of Hunan Province | PubMed | ||
| W20243173 | Health Research Project of Hunan Provincial Health Commission | PubMed |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39281564 | The role of ESM1 in the lipids metabolic reprogramming and angiogenesis of lung adenocarcinoma cells. | Heliyon | 2024 | https://conductscience.org/library/papers/39281564 | PubMed |
| 2 | 38897128 | Lactate drives the ESM1-SCD1 axis to inhibit the antitumor CD8+ T-cell response by activating the Wnt/β-catenin pathway in ovarian cancer cells and inducing cisplatin resistance. | Int Immunopharmacol | 2024 | https://conductscience.org/library/papers/38897128 | PubMed |
| 3 | 39545414 | Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation. | J Clin Invest | 2024 | https://conductscience.org/library/papers/39545414 | PubMed |
| 4 | 40132584 | Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi/MEKi-resistant melanoma. | Dev Cell | 2025 | https://conductscience.org/library/papers/40132584 | PubMed |
| 5 | 38212795 | ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1. | J Transl Med | 2024 | https://conductscience.org/library/papers/38212795 | PubMed |
| 6 | 39929852 | ESM1 promote proliferation, invasion and angiogenesis via Akt/mTOR and Ras pathway in kidney renal clear cell carcinoma. | Sci Rep | 2025 | https://conductscience.org/library/papers/39929852 | PubMed |
| 7 | 40089962 | ESM1 suppresses LncRNA GAS5/miR-23a-3p/PTEN axis to promote the cisplatin-chemotherapy resistance of ovarian cancer cells via activating the PI3K/AKT pathway. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40089962 | PubMed |
| 8 | 40073846 | Lactate: A key regulator of the immune response. | Immunity | 2025 | https://conductscience.org/library/papers/40073846 | PubMed |
| 9 | 40030031 | Dynamic investigation of hypoxia-induced L-lactylation. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40030031 | PubMed |
| 10 | 37653142 | Clinical and translational advances in ovarian cancer therapy. | Nat Cancer | 2023 | https://conductscience.org/library/papers/37653142 | PubMed |
| 11 | 36605187 | Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective. | Front Immunol | 2022 | https://conductscience.org/library/papers/36605187 | PubMed |
| 12 | 36593272 | Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma. | Nat Metab | 2023 | https://conductscience.org/library/papers/36593272 | PubMed |
| 13 | 38653238 | Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis. | Cell | 2024 | https://conductscience.org/library/papers/38653238 | PubMed |
| 14 | 36594088 | Validation of ESM1 Related to Ovarian Cancer and the Biological Function and Prognostic Significance. | Int J Biol Sci | 2023 | https://conductscience.org/library/papers/36594088 | PubMed |
| 15 | 40320451 | Unveiling the protective role of ESM1 in endothelial cell proliferation and lipid reprogramming. | Sci Rep | 2025 | https://conductscience.org/library/papers/40320451 | PubMed |
| 16 | 40314877 | Lactic acid metabolism: gynecological cancer's Achilles' heel. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40314877 | PubMed |
| 17 | 27189072 | Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N. | Diagn Pathol | 2016 | https://conductscience.org/library/papers/27189072 | PubMed |
| 18 | 21435938 | Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. | Drug Resist Updat | 2011 | https://conductscience.org/library/papers/21435938 | PubMed |
| 19 | 39642882 | Nuclear GTPSCS functions as a lactyl-CoA synthetase to promote histone lactylation and gliomagenesis. | Cell Metab | 2025 | https://conductscience.org/library/papers/39642882 | PubMed |
| 20 | 40113760 | Histone lactylation enhances GCLC expression and thus promotes chemoresistance of colorectal cancer stem cells through inhibiting ferroptosis. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40113760 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42780579 | Research progress on protein lactylation in female reproductive disease: molecular mechanisms, functions, and therapeutic implications. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42780579 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ESM1 | 11082 | PubTator's text mining | https://conductscience.org/library/genes/11082 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41555342
GET https://conductscience.org/api/papers/v1/41555342/references?page=2